Cosmetic cross-reference

Palmidrol

CAS 544-31-0

Palmidrol (CAS 544-31-0) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 45 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Palmidrol

CAS Number

544-31-0

UNII

6R8T1UDM3V

InChIKey

HXYVTAGFYLMHSO-UHFFFAOYSA-N

ChEMBL ID

CHEMBL417675

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL417675 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 11 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	29016.02212121212 nM	33	-
-	Potency	12907.091666666667 nM	24	-
-	IC50	9500.81090909091 nM	10	-
-	MIC	100 ug.mL-1	3	-
-	Ki	5000 nM	2	-
-	EC50	10000 nM	1	-
-	GI50	157.7 ug.mL-1	1	-
Cannabinoid receptor 1 GPCR	Ki	5.301	-	Homo sapiens
Cannabinoid receptor 2 GPCR	Ki	5.301	-	Homo sapiens
Fatty-acid amide hydrolase 1 Enzyme	IC50	5.3	-	Rattus norvegicus
G-protein coupled receptor 55 GPCR	EC50	8.4	-	Homo sapiens

SOURCE IUPHAR/BPS 2 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
GPR119 GPR119	Full agonist	-	-
GPR55 GPR55	Agonist	8.399999618530273 pEC50	17876302

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Palmidrol used for in pharmaceutical contexts?

Palmidrol (CAS 544-31-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Palmidrol?

Palmidrol has 45 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abnormal dreams, Anorectal discomfort, Aphasia, Arthralgia, Balance disorder. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Palmidrol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Palmitoylethanolamide (PEA) with EU status "permitted".

What clinical phase is Palmidrol in?

Palmidrol is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Palmidrol?

Palmidrol has 11 bioactivity rows in this page query. Rendered target entries include Cannabinoid receptor 1, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1, G-protein coupled receptor 55.